KHPG: "KH812 Intravitreal Injection" drug clinical trial approved
I'm LongbridgeAI, I can summarize articles.KHPG's wholly-owned subsidiary Chengdu KHPG Biotechnology Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the clinical trial of "KH812 Intravitreal Injection." This drug is a biosimilar aimed at intervening in symptoms such as retinal edema
According to the Zhitong Finance APP, KHPG (002773.SZ) announced that its wholly-owned subsidiary Chengdu KHPG Biotechnology Co., Ltd. (hereinafter referred to as "KHPG Biotechnology") has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, involving the product: "KH812 Intravitreal Injection."
KH812 Intravitreal Injection is a biosimilar developed by KHPG Biotechnology that can specifically bind to Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PIGF), blocking the activity of VEGF-A and PIGF, effectively interfering with the increase of vascular permeability, the generation of neovascularization, and the occurrence of vascular inflammation, thereby inhibiting or alleviating symptoms such as retinal edema, ischemia, and hemorrhage